Literature DB >> 22302754

Introduction to the series on microRNAs in the cardiovascular system.

Eva van Rooij1.   

Abstract

Until recently, microRNAs (miRNAs) were considered to be relatively small players in biological systems by having a balancing function through moderate effects on gene expression levels. However, it has become appreciated that miRNAs are actually much more relevant during both development and disease, which is underscored by the attention they have been receiving. The goal of this thematic review series is to highlight current knowledge of miRNA function during cardiovascular development, their dysregulation under disease conditions and the disease modifying functions they have been shown to exert in the cardiovascular system. These reviews, in addition to discussing the recent advancements in using miRNAs as circulating biomarkers or therapeutic modalities, will hopefully be able to provide a strong basis for future research to further expand our insights into miRNA function in cardiovascular biology.

Mesh:

Substances:

Year:  2012        PMID: 22302754     DOI: 10.1161/CIRCRESAHA.111.257311

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  11 in total

1.  Introduction to the series: challenges and opportunities in pediatric heart failure and transplantation.

Authors:  Daniel Bernstein
Journal:  Circulation       Date:  2014-01-07       Impact factor: 29.690

2.  Circulating Plasma Extracellular Vesicles from Septic Mice Induce Inflammation via MicroRNA- and TLR7-Dependent Mechanisms.

Authors:  Jinjin Xu; Yan Feng; Anjana Jeyaram; Steven M Jay; Lin Zou; Wei Chao
Journal:  J Immunol       Date:  2018-10-24       Impact factor: 5.422

3.  MicroRNA-302 increases reprogramming efficiency via repression of NR2F2.

Authors:  Shijun Hu; Kitchener D Wilson; Zhumur Ghosh; Leng Han; Yongming Wang; Feng Lan; Katherine J Ransohoff; Paul Burridge; Joseph C Wu
Journal:  Stem Cells       Date:  2013-02       Impact factor: 6.277

4.  Heart Failure in Chronic Myocarditis: A Role for microRNAs?

Authors:  P van den Hoogen; F van den Akker; J C Deddens; J P G Sluijter
Journal:  Curr Genomics       Date:  2015-04       Impact factor: 2.236

5.  The inverted pattern of circulating miR-221-3p and miR-222-3p associated with isolated low HDL-C phenotype.

Authors:  Yuntao Zhou; Mengdi Liu; Jinrong Li; Bing Wu; Wei Tian; Lu Shi; Jing Zhang; Zening Sun
Journal:  Lipids Health Dis       Date:  2018-08-16       Impact factor: 3.876

6.  Identification of Viscum album L. miRNAs and prediction of their medicinal values.

Authors:  Wenyan Xie; Jacob Adolf; Matthias F Melzig
Journal:  PLoS One       Date:  2017-11-07       Impact factor: 3.240

7.  Cardioprotective Effect of Danhong Injection against Myocardial Infarction in Rats Is Critically Contributed by MicroRNAs.

Authors:  Jingrui Chen; Jing Wei; John Orgah; Yan Zhu; Jingyu Ni; Lingyan Li; Han Zhang; Xiumei Gao; Guanwei Fan
Journal:  Evid Based Complement Alternat Med       Date:  2019-08-26       Impact factor: 2.629

8.  Decreased microRNA is involved in the vascular remodeling abnormalities in chronic kidney disease (CKD).

Authors:  Neal X Chen; Kraiwiporn Kiattisunthorn; Kalisha D O'Neill; Xianming Chen; Ranjani N Moorthi; Vincent H Gattone; Matthew R Allen; Sharon M Moe
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

Review 9.  Development of microRNA therapeutics is coming of age.

Authors:  Eva van Rooij; Sakari Kauppinen
Journal:  EMBO Mol Med       Date:  2014-07       Impact factor: 12.137

10.  Dexmedetomidine protects PC12 cells from ropivacaine injury through miR-381/LRRC4 /SDF-1/CXCR4 signaling pathway.

Authors:  Ying Xue; Tao Xu; Wei Jiang
Journal:  Regen Ther       Date:  2020-05-21       Impact factor: 3.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.